Get started
Author

Nischal Mahaveer Chand

Observed names: N.M. Chand, Nischal M. Chand, Nischal Mahaveer Chaud
OpenAlex ID: A5080474635
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia
2021 · Michael A. Kiebish, Poornima Tekumalla, et al. · Scientific Reports · 11
PDF
Establishing the relationship between brain cellular senescence and brain structure
2026 · Anina N. Lund, Brian H. Kopell, et al. · Cell · 6
Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men
2024 · Nischal Mahaveer Chand, Poornima K. Tekumalla, et al. · Cancers · 4
PDF
Hypothesis-Agnostic Network-Based Analysis of Real-World Data Suggests Ondansetron is Associated with Lower COVID-19 Any Cause Mortality
2022 · Gregory M. Miller, J. Austin Ellis, et al. · Drugs - Real World Outcomes · 3
PDF
A study of RNA splicing and protein expression in the living human brain
2025 · Brian H. Kopell, Deepak A. Kaji, et al. · PLoS ONE · 1
PDF
Abstract 1274: Integrated multiomics analysis identifies defective CoQ10 interactome in human kidney cancers.
2026 · Gregory M. Miller, Nischal Mahaveer Chaud, et al. · Cancer Research
Pan-cancer assessment of deletions in COQ biosynthesis pathway genes associated with poor prognosis and potential benefit from BPM31510 intervention in kidney cancers.
2026 · Nischal Mahaveer Chand, Michael Kiebish, et al. · Journal of Clinical Oncology
PDF
TMET-22. BPM31510 engagement of the Warburg effect in GBM to therapeutically modulate tumor metabolism through ROS mediated processes preclinically and clinically
2025 · Michael Kiebish, Vijay Modur, et al. · Neuro-Oncology
PDF
Abstract 5937: Development of a protein and clinical multiparametric biomarker panel for assessing pancreatic adenocarcinoma risk
2025 · Nischal Mahaveer Chand, A James Moser, et al. · Cancer Research
Abstract 4177: Integrated assessment of alterations in coenzyme Q biosynthesis genes impacting cancer metabolism leading to critical vulnerabilities in tumors
2025 · Nischal Mahaveer Chand, Eric M. Grund, et al. · Cancer Research
Analysis of lipogenic and metabolic subtypes and survival outcome in patients with pancreatic adenocarcinoma.
2025 · Madappa N. Kundranda, Nischal Mahaveer Chand, et al. · Journal of Clinical Oncology
Abstract 3527: Application of a deep learning based drug sensitivity prediction model on a novel anticancer drug
2024 · Nischal M. Chand, Vivek Vishnudas, et al. · Cancer Research
Abstract 3751: Diagnostic assessment of Filamin A (FLNA) as a serum biomarker for identification of benign prostatic hyperplasia vs aggressive prostate cancer in a prospective Mexican cohort
2024 · Arturo Rodriguez, Arturo Mendoza, et al. · Cancer Research
Abstract 2196: Serum Filamin A is a prognostic biomarker for screening benign prostatic hyperplasia vs prostate cancer in Caucasian and African American men
2023 · Nischal Mahaveer Chand, Poornima K. Tekumalla, et al. · Cancer Research
Abstract 5145: Project Survival®: Discovery of a molecular-clinical phenome biomarker panel to detect pancreatic ductal adenocarcinoma among at risk populations using high-fidelity longitudinal phenotypic and multi-omic analysis
2022 · Eric M. Grund, A. James Moser, et al. · Cancer Research
1485P Identification of novel protein biomarkers for FOLFIRINOX-based chemotherapy response in advanced pancreatic adenocarcinoma using patient omics and Bayesian AI
2021 · A.J. Moser, M. Kiebish, et al. · Annals of Oncology
PDF
1547P Project Survival®: High-fidelity longitudinal phenotypic and multi-omic characterization of pancreatic ductal adenocarcinoma (PDAC) for biomarker discovery
2020 · A.J. Moser, M.A. Kiebish, et al. · Annals of Oncology
Works count: 17
Citation count: 25
H-index: 3
I10-index: 1
Year
Topic
Type